|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Cheetah Medical Inc.'s BIOREACTANCE(R) Noninvasive Hemodynamic Monitoring Technology Found to Be a Promising Early Diagnostic Tool for Identification of Acute Heart Failure in the Emergency Department
5/18/2009 10:32:58 AM
TEL-AVIV, Israel & PORTLAND, Ore.--(BUSINESS WIRE)--Results from the first pilot study of Cheetah Medical’s early differential diagnostic protocol for acute heart failure were presented Thursday, May 14th, at the 2009 Society for Academic Emergency Medicine Annual Meeting in New Orleans. Heart failure exacerbations frequently manifest as shortness of breath, or “dyspnea.” Of over 119 million U.S. hospital emergency department visits in 2006, over 3 million were for the chief complaint of shortness of breath. In addition to heart failure, shortness of breath is associated with a variety of other diagnoses involving the lungs, heart and other organs, including chronic obstructive pulmonary disease (COPD), asthma, metabolic and psychiatric conditions. Early, correct diagnosis and management is key to improve outcomes while relieving heavy patient burdens in hospital emergency departments.
|
|
|
|
|
|
|
|
|
|
|